The Intellectual Property Core provides support services to Seattle Children’s faculty, staff and workforce members related to intellectual property they develop at Seattle Children’s. The Intellectual Property Core’s goal is to help researchers and clinicians evaluate their technologies for commercialization, protect their ideas through the patent or copyright process, and transfer technologies into the marketplace via out-licensing and startup formation. We encourage companies to engage with our investigators to further the value and impact of our research. This process allows Seattle Children’s to bring technologies into the real world to benefit pediatric patients and their families, while generating revenue that supports further research activities.
In the News
-
October 22, 2020
Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines
The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs. David Rawlings and Richard James at Seattle Children’s Research Institute.
-
August 5, 2020
GentiBio Launches to Develop Engineered Regulatory T cells for Autoimmune and Inflammatory Diseases
GentiBio enters exclusive licensing partnerships for proprietary regulatory T cell engineering technologies with Seattle Children's Research Institute, Benaroya Research Institute and MIGAL Galilee Research Institute.
-
June 2, 2020
CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases
The alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases – Wiskott-Aldrich Syndrome and X-linked Agammaglobulinemia.
-
May 29, 2020
Scientists Developing Diagnostic Test for Childhood Disease Linked to Covid-19
Seattle Children’s scientists are collaborating with Prevencio Inc. to use artificial intelligence in an attempt to develop the first diagnostic test for Kawasaki disease that will be available for widespread use. (Wall Street Journal)
-
May 14, 2020
Scientists Developing Diagnostic Test for Childhood Disease Linked to Covid-19
The US Department of Defense has awarded Draper, Boston Children’s Hospital and Seattle Children’s Research Institute a $4.3 million, three-year grant to explore the feasibility of treating congenital heart defects in children using a growth-adaptive pediatric heart valve. (PRWeb)
-
May 9, 2019
Seattle Children’s Research Institute and bluebird Focus on Next-Generation Gene and Cell Therapies
Seattle Children’s Research Institute and bluebird bio have announced a new research collaboration for acute myeloid leukemia, specifically targeting the heterogeneity of the disease as well as the salvage of normal tissues with the potential for on-target/off-tumor targeting. (bluebird bio)
-
September 27, 2017
Seattle Children’s Licenses Gene-editing Therapy to Casebia Therapeutics and Will Partner on Further Research
Seattle Children’s and Casebia and will work together to further develop the technology and use it to create new treatments and preventions for autoimmune diseases. (GeekWire)